Dr. Mikhail Blagosklonny publishes the Oncotarget as its Editor-in-Chief. Oncotarget publishes online articles twice a week, regarding leading and innovative oncology treatments and breakthroughs. Dr. Blagosklonny publishes and contributes to journals like “Cell Cycle,” Cell Death and Differentiation, Cancer Biology/Therapy, and many other international journals on cancer research.
Mikhail V. Blagosklonny, M.D., Ph.D., attended the First Pavlov State Medical University located in St. Petersburg, Russia. Dr. Blagosklonny acquired his degrees in Internal Medicine and Experimental Medicine and Cardiology. Mikhail also had a keen interest in cancer because it is a disease that takes the life of so many people. Read Mikhail’s plans for Oncology on Healingmagic.net.
Dr. Blagosklonny’s medical studies at First Pavlov State Medical University was focused on anti-aging research, molecular studies, Biogerontology, and other studies within the cancer research field. Mikhail Blagosklonny is renowned in different unique medical fields which he excels in, including his work as a researcher and author. He has authored many prominent research citations and medical review papers that are recognized by his peers as leading medical publications.
Currently, he is a professor and scientist of Oncology at the Roswell Park Cancer Institute in New York. The earlier career successes of Dr. Mikhail Blagosklonny have included his appointment as Associate Professor of Medicine at New York Medical College and as the lead scientist at the Ordway Research Institute in New York. Know more about Mikhail at Philly Purge.
Dr. Mikhail’s tenaciousness in the oncology field cancer is based on his belief that cancer and much of its harmful tentacles can be cured. For this reason, he is supporting a formula called “Rapamycin” or “Sirolimus.” Within the pharmaceutical industry, the drug is known as “Rapamune.” Dr. Blagosklonny touts Rapamune for its proven benefits in arresting many cancer-related issues.
The Rapamune benefits have proven that it is a safe and effective drug that can be used after an organ transplant, protects coronary stents, tumor regressive results, cures facial angiofibromas, and is a healing drug that helps in other diseases like Alzheimer, lung disease, and muscular dystrophy. Dr. Blagosklonny continues to support continued research on this drug because it shows great promise in a variety of ailments that can help to increase the life span of man.